Boston Scientific keeps Penumbra deal on track as Penumbra stock costs EUR 284.00

Published on 10/02/2026 at 12:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 14.90 percent to USD 390.05 million. Penumbra stock costs EUR 284.00 on October 2, 2026 after EUR 282.80.

PEN, US70975L1070, Illustration mit AI erstellt.

Penumbra, Inc. (US70975L1070) was trading at EUR 284.00 at Lang & Schwarz on October 2, 2026 at 12:06 p.m. CEST, up 0.42 percent versus the prior close of EUR 282.80. The key corporate development is Boston Scientific's planned acquisition, which management said remained on track for completion by year-end 2026 on September 10, 2026.

Acquisition remains on track

As Investing.com reported on September 10, 2026, Boston Scientific said integration planning for Penumbra was already under way and that the transaction remained scheduled to close by the end of 2026. The update keeps the acquisition timeline central to Penumbra's market story while the company continues operating as a standalone medical-device business.

The transaction also creates an operating counterweight. Penumbra's second-quarter release identified USD 6.9 million of acquisition-related expenses, while the company provided no full-year 2026 financial guidance because of the pending deal.

Revenue grows, earnings miss

According to Trivano in the release dated July 30, 2026, Penumbra generated USD 390.05 million of revenue in the second quarter of 2026, an increase of 14.90 percent from the second quarter of 2025. Global thrombectomy revenue reached USD 259.00 million, up 12.50 percent, while embolization and access revenue rose 20.00 percent to USD 131.10 million.

The earnings picture was weaker than the sales trend. Diluted earnings per share were USD 0.88 in the second quarter of 2026, below the USD 1.16 consensus estimate cited by MarketBeat, while net income reached USD 34.81 million and operating margin was 11.00 percent. Revenue therefore exceeded the USD 389.64 million consensus estimate, but earnings per share missed by USD 0.28.

Stock stays below its yearly high

Penumbra's primary listing is on the NYSE, where the stock was last quoted at USD 318.00 on October 1, 2026 at 4:00 p.m. ET. Its 52-week range was USD 221.26 to USD 362.41 on that date, and the market capitalization was USD 12.5 billion.

The market is weighing a fast-growing sales base against lower quarterly earnings and the execution demands of a pending combination. Penumbra held USD 205.27 million in cash and cash equivalents on June 30, 2026, giving the balance sheet a concrete role in that assessment.

Penumbra stock at Lang & Schwarz

Penumbra stock was trading at EUR 284.00 at Lang & Schwarz on October 2, 2026 at 12:06 p.m. CEST, plus 0.42 percent versus the prior close of EUR 282.80 on October 1, 2026.